LLY

928.56

+2.46%↑

JNJ

186.29

-0.27%↓

UNH

327.86

-0.81%↓

NVS

125.19

+0.06%↑

ABT

124.68

-0.87%↓

LLY

928.56

+2.46%↑

JNJ

186.29

-0.27%↓

UNH

327.86

-0.81%↓

NVS

125.19

+0.06%↑

ABT

124.68

-0.87%↓

LLY

928.56

+2.46%↑

JNJ

186.29

-0.27%↓

UNH

327.86

-0.81%↓

NVS

125.19

+0.06%↑

ABT

124.68

-0.87%↓

LLY

928.56

+2.46%↑

JNJ

186.29

-0.27%↓

UNH

327.86

-0.81%↓

NVS

125.19

+0.06%↑

ABT

124.68

-0.87%↓

LLY

928.56

+2.46%↑

JNJ

186.29

-0.27%↓

UNH

327.86

-0.81%↓

NVS

125.19

+0.06%↑

ABT

124.68

-0.87%↓

Search

Pfizer

Geschlossen

BrancheGesundheitswesen

24.59 1.15

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

24.16

Max

24.66

Schlüsselkennzahlen

By Trading Economics

Einkommen

-45M

2.9B

Verkäufe

938M

15B

KGV

Branchendurchschnitt

13.106

37.003

EPS

0.78

Dividendenrendite

6.87

Gewinnspanne

19.982

Angestellte

81,000

EBITDA

266M

5.3B

Empfehlungen

By TipRanks

Empfehlungen

Neutral

12-Monats-Prognose

+18.77% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

6.87%

2.25%

Nächste Dividendenausschüttung

1. Dez. 2025

Nächstes Ex-Dividendendatum

7. Nov. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

7.1B

141B

Vorheriger Eröffnungskurs

23.44

Vorheriger Schlusskurs

24.59

Nachrichtenstimmung

By Acuity

52%

48%

298 / 373 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Bullish Evidence

Pfizer Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

4. Nov. 2025, 12:29 UTC

Ergebnisse
Akquisitionen, Fusionen, Übernahmen

Pfizer 3Q Profit Falls Amid Lower Covid-19 Drug Demand -- Update

4. Nov. 2025, 12:12 UTC

Ergebnisse

Pfizer 3Q Profit Falls Amid Lower Covid-19 Drug Demand

4. Nov. 2025, 22:10 UTC

Akquisitionen, Fusionen, Übernahmen

Pfizer, Novo Nordisk Escalate Bidding War for Weight-Loss Drug Startup -- 2nd Update

4. Nov. 2025, 19:39 UTC

Akquisitionen, Fusionen, Übernahmen

Pfizer, Novo Nordisk Escalate Bidding War for Weight-Loss Drug Startup -- Update

4. Nov. 2025, 18:35 UTC

Akquisitionen, Fusionen, Übernahmen

Novo Nordisk Is Still Beating Pfizer in Battle Over Metsera -- Barrons.com

4. Nov. 2025, 18:11 UTC

Ergebnisse

Pfizer 3Q Profit Falls Amid Lower Covid-19 Drug Demand -- 2nd Update

4. Nov. 2025, 17:59 UTC

Ergebnisse

Pfizer Stock Slips. Under the Surface, Earnings Weren't Great. -- Barrons.com

4. Nov. 2025, 17:26 UTC

Akquisitionen, Fusionen, Übernahmen

Novo Nordisk Is Still Beating Pfizer in Battle Over Metsera -- Barrons.com

4. Nov. 2025, 16:01 UTC

Akquisitionen, Fusionen, Übernahmen

Pfizer, Novo Nordisk Escalate Bidding War for Weight-Loss Drug Startup -- WSJ

4. Nov. 2025, 15:17 UTC

Akquisitionen, Fusionen, Übernahmen

Novo Nordisk and Pfizer Sweeten Their Offers for Weight-Loss Drug Startup Metsera -- WSJ

4. Nov. 2025, 14:58 UTC

Akquisitionen, Fusionen, Übernahmen

Novo Nordisk Sweetens Offer for Metsera -- WSJ

4. Nov. 2025, 14:37 UTC

Akquisitionen, Fusionen, Übernahmen

Novo Nordisk: Proposal Is Subject to Terms of Pfizer's Merger Pact With Metsera

4. Nov. 2025, 14:35 UTC

Akquisitionen, Fusionen, Übernahmen

Novo Nordisk Says Offer Highlights Commitment to Investing in U.S., Interest in Growing Scale of U.S. Investments

4. Nov. 2025, 14:34 UTC

Akquisitionen, Fusionen, Übernahmen

Novo Nordisk Believes Proposal, Including Structure, Complies With Applicable Laws and Is in Best Interest of Patients

4. Nov. 2025, 14:33 UTC

Akquisitionen, Fusionen, Übernahmen

Novo Nordisk Offers $62.20 a Share in Cash and Up to $24 a Share Based on Certain Milestones

4. Nov. 2025, 14:32 UTC

Akquisitionen, Fusionen, Übernahmen

Novo Nordisk Confirms Updated Bid For Metsera

4. Nov. 2025, 14:12 UTC

Akquisitionen, Fusionen, Übernahmen

Metsera Says Pfizer Merger Agreement Remains in Effect >MTSR

4. Nov. 2025, 14:12 UTC

Akquisitionen, Fusionen, Übernahmen

Metsera, Pfizer May Negotiate Potential Adjustments for Two Business Days >MTSR

4. Nov. 2025, 14:12 UTC

Akquisitionen, Fusionen, Übernahmen

Metsera: Novo Nordisk Offer Superior to Revised Pfizer Proposal That Valued It at Up to $ 70/Shr, a Total of About $8.1B >MTSR

4. Nov. 2025, 14:11 UTC

Akquisitionen, Fusionen, Übernahmen

Metsera: Novo Nordisk's Amended Proposal Values It at Up to $ 86.20/Shr, a Total of About $ 10.0B >MTSR

4. Nov. 2025, 14:10 UTC

Akquisitionen, Fusionen, Übernahmen

Metsera Receives Amended Proposal From Novo Nordisk; Metsera Declares Novo Nordisk Amended Proposal 'Superior'

4. Nov. 2025, 12:37 UTC

Ergebnisse
Akquisitionen, Fusionen, Übernahmen

Pfizer Stock Slips on Third-Quarter Earnings. What Covid-19 Has to Do With It. -- Barrons.com

4. Nov. 2025, 12:02 UTC

Ergebnisse

Pfizer Stock Rises on Third-Quarter Earnings. Here's Why. -- Barrons.com

4. Nov. 2025, 11:49 UTC

Ergebnisse

Pfizer: On Track to Deliver $7.2B Net Cost Savings From Cost-Improvement Initiatives by End 2027 >PFE

4. Nov. 2025, 11:47 UTC

Ergebnisse

Pfizer: Expect to Continue to De-Lever in Prudent Manner to Maintain Balanced Capital-Allocation Strategy >PFE

4. Nov. 2025, 11:47 UTC

Ergebnisse

Pfizer: Current Financial Guidance Doesn't Anticipate Any Share Buybacks in 2025 >PFE

4. Nov. 2025, 11:46 UTC

Ergebnisse

Pfizer: 2025 Guidance Absorbs Impact of Currently Imposed Tariffs From China, Canada, Mexico >PFE

4. Nov. 2025, 11:46 UTC

Ergebnisse

Pfizer Backs 2025 View of Rev $61B-$64B >PFE

4. Nov. 2025, 11:45 UTC

Ergebnisse

Pfizer Had Seen 2025 Adjusted EPS $2.90-$3.10 >PFE

4. Nov. 2025, 11:45 UTC

Ergebnisse

Pfizer 3Q Rev $16.65B >PFE

Peer-Vergleich

Kursveränderung

Pfizer Prognose

Kursziel

By TipRanks

18.77% Vorteil

12-Monats-Prognose

Durchschnitt 28.86 USD  18.77%

Hoch 34 USD

Tief 24 USD

Basierend auf 16 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Pfizer – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

16 ratings

4

Buy

11

Halten

1

Sell

Technischer Score

By Trading Central

22.855 / 23.85Unterstützung & Widerstand

Kurzfristig

Bullish Evidence

Mittelfristig

Bearish Evidence

Langfristig

Bearish Evidence

Stimmung

By Acuity

298 / 373 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bärische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Pfizer

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as has strategic clinical collaboration with Acepodia Inc. for the development of antibody-cell conjugation-based cell therapies in autoimmune diseases. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
help-icon Live chat